Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04042701
Title DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Daiichi Sankyo, Inc.

lung non-small cell carcinoma

Her2-receptor positive breast cancer


Pembrolizumab + Trastuzumab deruxtecan

Age Groups: adult | senior
Covered Countries USA | FRA | ESP

No variant requirements are available.